Search clinical trials for: ONO-1101

Total 14563 results

M.D. Anderson Cancer Center

Recruiting

Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditions

United States
Scioderm, Inc.
Amicus Therapeutics

Completed

ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Epidermolysis Bullosa

Italy, Spain, Serbia, United States, Australia, Netherlands, Austria, Germany, Israel, Lithuania, France, United Kingdom, Poland
Emory University
Bristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...

Active, not recruiting

Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer

Colorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis

Primary Myelofibrosis | Splenomegaly | Hepatomegaly | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential Thrombocythemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Kythera Biopharmaceuticals

Completed

Open-Label Pharmacokinetic Study of Final Formulations of ATX-101

Healthy

United States
Ono Pharmaceutical Co. Ltd
Parexel

Completed

A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of ONO-2808-01 in Healthy Participants

Neurodegenerative Diseases

United Kingdom
Ono Pharmaceutical Co. Ltd

Completed

A Human Mass Balance Study to Determine the Total Recovery of Radioactivity in Urine and Faeces Following a Single Oral Dose of 14C Radiolabelled ONO-4053

Healthy Adult Male Subjects

United Kingdom
Ono Pharmaceutical Co. Ltd

Completed

A Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of ONO-4053 in Healthy Volunteers

Healthy Adult Subjects

United Kingdom
Ono Pharmaceutical Co. Ltd

Terminated

A Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of ONO-4053 in Healthy Volunteers

Healthy Adult Subjects

United Kingdom
Ono Pharma USA Inc

Completed

Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects

Healthy Adult Subjects

United States
RenJi Hospital

Recruiting

Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)

Familial Hypercholesterolemia

China
Forge Biologics, Inc

Not yet recruiting

Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients

Krabbe Disease

United States
University of Colorado, Denver
Tvardi Therapeutics, Incorporated

Recruiting

Trial of Radiotherapy in Combination With TTI-101 in Patients With Borderline Resectable Pancreatic Cancer

Pancreatic Cancer

United States
Bright Cell, Inc.

Not yet recruiting

BC-101 in Treatment of Nasolabial Fold Wrinkles

Nasolabial Fold Wrinkles
Seoul National University Hospital
Pharos iBio Co., Ltd.

Recruiting

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML

Relapsed or Refractory Acute Myeloid Leukemia

Korea, Republic of
4D Molecular Therapeutics

Active, not recruiting

Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia

Choroideremia

United States
Perceive Biotherapeutics, Inc.

Active, not recruiting

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Age-related Macular Degeneration | Geographic Atrophy

United States
REGENXBIO Inc.

Active, not recruiting

RGX-111 Gene Therapy in Patients With MPS I

Hurler Syndrome | Hurler-Scheie Syndrome | Mucopolysaccharidosis Type I (MPS I)

United States, Brazil, Israel
Abeona Therapeutics, Inc

Enrolling by invitation

A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

RDEB

United States
Sentien Biotechnologies, Inc.

Active, not recruiting

A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy

COVID-19 | Sepsis | Acute Kidney Injury

United States
Jazz Pharmaceuticals

Completed

"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" (OSA)

Obstructive Sleep Apnea

United States, Finland, Germany, France, Sweden
Healthpoint

Completed

Contact Sensitization Potential of 828 Ointment

Healthy Volunteers

United States
BioMarin Pharmaceutical

Approved for marketing

BMN 110 US Expanded Access Program

Morquio A Syndrome | MPS IVA | Mucopolysaccharidosis IVA

United States, Puerto Rico
ChemomAb Ltd.

Completed

The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects

Nonalcoholic Fatty Liver Disease

Israel
Eisai Inc.
Bliss Biopharmaceutical (Hangzhou) Co., Ltd

Recruiting

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Breast Cancer

United States, Japan
Eledon Pharmaceuticals

Terminated

Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

IgA Nephropathy | IgAN

Australia, Spain, Thailand, New Zealand, Croatia, Malaysia, Philippines, Poland, Sri Lanka, United Kingdom
Immunovant Sciences GmbH

Completed

Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)

Graves' Ophthalmopathy

Canada
Boryung Biopharma Co., Ltd.

Completed

To Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children

Tetanus | Diphtheria

Korea, Republic of
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

Central Nervous System Neoplasm | Solid Neoplasm | Recurrent Acute Leukemia | Refractory Acute Leukemia | Infantile Fibrosarcoma

United States, Canada
Emerald Health Pharmaceuticals

Completed

To Evaluate the Safety and Tolerability, Pharmacokinetics, Food-effect and Pharmacodynamics of EHP-101 in Healthy Volunteers

Healthy

Australia
Onconova Therapeutics, Inc.

Completed

Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

United States, France
Chinook Therapeutics, Inc.

Active, not recruiting

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

IgA Nephropathy

Korea, Republic of, United States, United Kingdom
Scioderm, Inc.
Food and Drug Administration (FDA); Amicus Therapeutics

Terminated

Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Epidermolysis Bullosa

United States
Roswell Park Cancer Institute

Completed

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | EGFR Gene Mutation

United States
TG Therapeutics, Inc.

Active, not recruiting

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis (RMS)

United States, Belarus, Croatia, Georgia, Poland, Russian Federation, Serbia, Ukraine
Providence Health & Services

Recruiting

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

BRAF V600E Mutation Present | Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8 | Refractory Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | BRAF NP_004324.2:p.V600M | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8 | Stage IVB Differentiated Thyroid Gland Carcinoma...

United States
Ono Pharmaceutical Co. Ltd
Bristol-Myers Squibb

Completed

Study of Adjuvant ONO-4538 With Resected Gastric Cancer

Gastric Cancer

China, Japan, Korea, Republic of, Taiwan
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Richter Syndrome | Indolent Non-Hodgkin Lymphoma

United States
Neurona Therapeutics
California Institute for Regenerative Medicine (CIRM)

Recruiting

FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis

United States
Light Chain Bioscience - Novimmune SA

Completed

Study of an Anti-TLR4 mAb in Rheumatoid Arthritis

Rheumatoid Arthritis

Serbia, Bosnia and Herzegovina, Bulgaria, Georgia, Hungary, Moldova, Republic of, Poland
9 Meters Biopharma, Inc.
Teva Pharmaceuticals USA

Completed

A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

Celiac Disease

United States, Canada
9 Meters Biopharma, Inc.

Completed

Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects

Celiac Disease

United States
M.D. Anderson Cancer Center

Active, not recruiting

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8

United States
AL-S Pharma

Recruiting

A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Korea, Republic of, United States, Canada, Germany, Sweden, Belgium
QurAlis Corporation

Completed

A Study Evaluating Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Participants

Healthy Volunteers

Netherlands
Veloxis Pharmaceuticals

Completed

A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

Healthy Volunteers

United States
Veru Inc.

Completed

VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study (VERU-111)

SARS-CoV Infection

United States, Argentina, Brazil, Bulgaria, Colombia, Mexico
Veru Inc.

Completed

COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111

Respiratory Distress Syndrome, Adult

United States
Inversago Pharma Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects

Pharmacokinetic

Canada

Search clinical trials for: ONO-1101

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations